Organon & Co. (OGN) Projected to Post Earnings on Thursday

Key Points

• Organon was expected to report Q1 2026 results on May 7 with analysts forecasting $0.84 EPS and $1.4983B in revenue, but the company canceled its Q1 earnings call after announcing a pending agreement with Sun Pharma.
• The proposed Sun Pharma transaction reportedly values the deal at about $11.75 billion and offers shareholders $14.00 per share, lifting the stock to 52‑week highs and prompting broker price-target increases to roughly $14.00.
• Despite the deal premium, law firms have launched investigations into the fairness of the $14 price, MarketBeat shows an average analyst rating of "Reduce" with an average target of $11.40, and institutional investors own about 77% of the shares.

Organon & Co. (NYSE:OGN - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Organon & Co. to post earnings of $0.84 per share and revenue of $1.4983 billion for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The company had revenue of $1.51 billion for the quarter, compared to analysts' expectations of $1.52 billion. During the same quarter in the prior year, the company earned $0.90 EPS. The company's revenue was down 5.3% on a year-over-year basis. On average, analysts expect Organon & Co. to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Organon & Co. Trading Up 0.1%

Shares of OGN stock opened at $13.34 on Thursday. The company has a debt-to-equity ratio of 11.47, a quick ratio of 1.23 and a current ratio of 1.82. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.38. The company has a market capitalization of $3.50 billion, a PE ratio of 18.79, a price-to-earnings-growth ratio of 1.22 and a beta of 0.67. The business's fifty day moving average is $7.57 and its 200 day moving average is $7.72.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Monday, February 23rd were given a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, February 23rd. Organon & Co.'s dividend payout ratio (DPR) is 11.27%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC increased its stake in Organon & Co. by 23.2% in the third quarter. Parallel Advisors LLC now owns 16,014 shares of the company's stock valued at $171,000 after acquiring an additional 3,020 shares during the last quarter. Hsbc Holdings PLC increased its stake in Organon & Co. by 17.2% in the fourth quarter. Hsbc Holdings PLC now owns 22,953 shares of the company's stock valued at $165,000 after acquiring an additional 3,373 shares during the last quarter. Aristeia Capital L.L.C. bought a new position in shares of Organon & Co. during the fourth quarter valued at about $162,000. Gamco Investors INC. ET AL bought a new position in shares of Organon & Co. during the second quarter valued at about $119,000. Finally, BTG Pactual Asset Management US LLC bought a new position in shares of Organon & Co. during the fourth quarter valued at about $117,000. Institutional investors own 77.43% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on OGN shares. Barclays increased their price objective on Organon & Co. from $7.50 to $8.00 and gave the stock an "underweight" rating in a research report on Tuesday, February 24th. Zacks Research upgraded Organon & Co. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 14th. Wall Street Zen downgraded Organon & Co. from a "buy" rating to a "hold" rating in a research report on Saturday, January 31st. Piper Sandler upgraded Organon & Co. from an "underweight" rating to a "neutral" rating and increased their price objective for the stock from $5.00 to $14.00 in a research report on Tuesday. Finally, BNP Paribas Exane reiterated a "neutral" rating and issued a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research report on Wednesday. Four research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Organon & Co. presently has an average rating of "Reduce" and an average price target of $11.40.

Trending Headlines about Organon & Co.

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Sun Pharma deal and cash consideration provide a clear floor (shareholders to receive $14.00 per share), lifting M&A bidders’ enthusiasm and pushing the stock to 52-week highs. Organon & Co. (OGN) Soars to 52-Week High on $11.75-Billion Sun Merger
• Positive Sentiment: Piper Sandler upgraded OGN from underweight to neutral and set a $14.00 price target, signaling dealer support for the transaction price and narrowing downside risk. Piper Sandler upgrade
• Neutral Sentiment: Organon canceled its Q1 earnings call because of the announced agreement with Sun Pharma — a procedural step reflecting the pending deal rather than new operational news. Organon Cancels First Quarter Earnings Call
• Neutral Sentiment: BNP Paribas Exane reaffirmed a neutral rating and raised its price target to $14.00 (up from $12.00), aligning the street around the deal price while stopping short of a buy endorsement. BNP Paribas Exane reaffirmation
• Negative Sentiment: Law firms (Kahn Swick & Foti and Halper Sadeh) have launched investigations into whether the $14.00 cash price and the sale process are fair to shareholders — these inquiries can lead to litigation, potential delays, or renegotiation. Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon Co. - OGN
• Negative Sentiment: BNP Paribas Exane previously moved OGN from strong‑buy to hold (coverage adjustment), signaling reduced enthusiasm from a formerly bullish analyst and potentially limiting further upside absent a competing bidder or higher offer. Analyst downgrade

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.